Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions noted, no amendment

The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.

Submissions

109 documents · page 1 of 4

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-CERTAINTY-FR/006Draft revision of the Institute’s certainty assessment framework…Dr Lorcan Whitmarsh-ObiThe document should describe how an assessment becomes a decision
DRAFT-SUPPLIER-RUB/002Draft supplier evaluation rubricGeorgiana ZimmerthalDeclared interests should appear on the document rather than on a separate page
DRAFT-SEMAGLUTIDE-/009Draft monograph: semaglutide, version 3Vittoria YlönenThe monograph should not describe how the compound is supplied outside a regulated route
DRAFT-TIRZEPATIDE-/004Draft monograph: tirzepatide, version 2Dr Xenia Nyquist-ObioraGuidance on lyophilised storage is missing
DRAFT-WEIGHT-REGAI/008Draft synthesis: weight change after discontinuation of an incretin…Dr Yaa KettlewellBaseline imbalance in a small contributing trial is not remarked on
DRAFT-FUNDING-POLI/004Draft funding and sponsorship policyKamila UbertiniThe Institute publishes no telephone number and no messaging channel
DRAFT-CITATION-POL/007Draft citation policyDr Perpetua Haverkamp-Diallo industryThe disclosure requirements exceed those of comparable bodies
DRAFT-PROGRAMME-RE/004Draft policy: labelling of Institute-constructed programme recordsKolawole Oppenheimer-AdeThe Institute publishes no telephone number and no messaging channel
DRAFT-ENDOTOXIN-ST/004Draft standard: bacterial endotoxin testing of peptide presentationsStellan Cholmondeley-AdeA superseded version should remain reachable from the version that replaced it
DRAFT-GLP1-OBESITY/015Draft synthesis: glucagon-like peptide-1 receptor agonists for weight…Georgiana ZimmerthalDeclared interests should appear on the document rather than on a separate page
DRAFT-THYROID-C-CE/008Draft safety review: the rodent thyroid C-cell signal and its human…Dr Yaa KettlewellBaseline imbalance in a small contributing trial is not remarked on
DRAFT-THYROID-C-CE/010Draft safety review: the rodent thyroid C-cell signal and its human…Dr Emiliana OllerenshawDeclared interests should appear on the document rather than on a separate page
DRAFT-SUPPLIER-DOS/005Draft format of the supplier dossier seriesUlysses Bellingham-OjoA multi-part document does not indicate how many parts it has
DRAFT-PEOPLE-REGIS/002Draft policy on the register of members and reviewersDr Beatrijs HazelriggAssessment committee meetings are held in private
DRAFT-PEOPLE-REGIS/006Draft policy on the register of members and reviewersKolawole Oppenheimer-AdeThe Institute publishes no telephone number and no messaging channel
DRAFT-PEOPLE-REGIS/008Draft policy on the register of members and reviewersVittoria YlönenDeclared interests should appear on the document rather than on a separate page
DRAFT-PEOPLE-REGIS/013Draft policy on the register of members and reviewersWilhelmina ErlingssonA submission the Institute declines to publish leaves no trace
DRAFT-CORRECTIONS-/007Draft corrections and versioning policyGeorgiana ZimmerthalDeclared interests should appear on the document rather than on a separate page
DRAFT-CORRECTIONS-/017Draft corrections and versioning policyDr Perpetua Haverkamp-Diallo industryThe disclosure requirements exceed those of comparable bodies
DRAFT-STABILITY-ST/011Draft standard: freeze–thaw and in-use stability assessment of…Vittoria YlönenDeclared interests should appear on the document rather than on a separate page
DRAFT-INDICATION-S/008Draft indication set and anchor outcomesAnselm MountstephenA superseded version should remain reachable from the version that replaced it
DRAFT-ADOLESCENT-S/011Draft synthesis: incretin receptor agonists in adolescentsDr Oisín RautavaaraBaseline imbalance in a small contributing trial is not remarked on
DRAFT-ADOLESCENT-S/016Draft synthesis: incretin receptor agonists in adolescentsQuentin Whitmarsh-ObiA superseded version should remain reachable from the version that replaced it
DRAFT-ANALYTICAL-S/005Draft analytical review: surveys of unregulated peptide supplyDr Anselm Thorsby-NakamuraThe chain of custody between purchase and analysis is not described
DRAFT-ANALYTICAL-S/007Draft analytical review: surveys of unregulated peptide supplyGervase CrickhowellWhether the analyst knew the source of each sample is not reported
DRAFT-ANALYTICAL-S/008Draft analytical review: surveys of unregulated peptide supplyProfessor Bartolomeu Nkosi-LindegaardContributing surveys anonymise their sources to different degrees
DRAFT-ANALYTICAL-S/013Draft analytical review: surveys of unregulated peptide supplyStellan Cholmondeley-AdeA superseded version should remain reachable from the version that replaced it
DRAFT-REGISTRY-STR/003Draft structure of the document registryDr Emiliana OllerenshawDeclared interests should appear on the document rather than on a separate page
DRAFT-TOOLS-DISCLA/006Draft terms for the Institute’s calculatorsKolawole Oppenheimer-AdeThe Institute publishes no telephone number and no messaging channel
DRAFT-TOOLS-DISCLA/011Draft terms for the Institute’s calculatorsAmara VandergraafA submission the Institute declines to publish leaves no trace

page 1 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.